for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-CSPC Pharmaceutical Group receives U.S.FDA orphan-drug designation for malignant tumour treatment drug

Sept 27 (Reuters) - CSPC Pharmaceutical Group Ltd

* Group’s Malignant Tumour Treatment Drug “Mitoxantrone Hydrochloride Liposome’ was granted orphan-drug designation by the U.S. FDA

* Mitoxantrone Hydrochloride Liposome is currently under phase ii clinical trial in China Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up